*Events listed are provided as a service to our members and should not be interpreted as an endorsement or recommendation by the WANP for any specific subject or content.
- This event has passed.
Genetic Markers and Personalized Treatment in Psychiatry: Webinar
May 1 @ 6:00 pm - 7:00 pm
Genetic Markers and Personalized Treatment in Psychiatry
May 1, 2019 6 – 7 pm
Presenter: Russell Amato, PhD – Medical Science Liaison, Genomind, Inc
This focus of this webinar will be to provide an introduction to ‘Genetics 101’ in the context of pharmaceutical treatment of mental health conditions in primary care.
The presentation will address the use of genetic markers to assist in the selection of medications for the treatment of a variety of mental health conditions, such as anxiety, depression and bipolar disorder.
Specific topics will include a review of molecular genetics, single nucleotide polymorphisms (SNPs) and related factors.
This no-cost program is open to all WANP members. Attendees will receive an electronic certificate for 1.0 CEU.
Speaker Information: Dr. Russell Amato received his PhD in Pharmacology at Louisiana State University and has over a decade of experience in developing novel therapeutics for neuropsychiatric diseases including drug abuse, depression, anxiety and ADHD. His PhD work focused on the evaluation of neuroactive steroids in preclinical models of alcohol addiction, as well as assessing these compounds for their potential utility in cognitive disorders. He completed his postdoctoral fellowship within the Vanderbilt Center for Neuroscience Drug Discovery, where he evaluated metabotropic glutamate receptor negative allosteric modulators for the treatment of cocaine addiction, in addition to evaluating these compounds for use in depressive/anxiety disorders. Before coming to Genomind, Dr. Amato also worked on the development of antisense oligonucleotides as a novel therapy for genetic polymorphisms in a preclinical model of Usher Syndrome, providing him with a strong background in both genetics and psychiatric disease.
Disclosure: Genomind is a corporate sponsor of the WANP.